Plerixafor is a CXC chemokine receptor (CXCR4) antagonist that mobilizes stem cells in the peripheral blood. It is indicated (in combination with granulocyte-colony stimulating factor [G-CSF] 
delayed re-mobilization after a failed mobilization attempt with G-CSF, and rescue or pre-emptive mobilization in patients in whom mobilization with G-CSF is likely to fail. Pre-emptive use has the advantage that it avoids the need to re-schedule the transplant procedure, with its attendant inconvenience, quality-of-life issues for the patient and cost of additional admissions to the transplant unit. UK experience from 2 major centers suggests that pre-emptive plerixafor is associated with an incremental drug cost of less than £2000 when averaged over all patients undergoing peripheral blood stem cell (PBSC) transplant. A CD341 cell count of <15 ml 21 at the time of recovery after chemomobilization or after four days of G-CSF treatment, or an apheresis yield of <1 3 10 6 CD341 cells/kg on the first day of apheresis, could be used to predict the need for pre-emptive plerixafor.
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| I NT ROD UCTI ON AND B ACKG ROU ND
High dose chemotherapy with autologous peripheral blood stem cell (PBSC) rescue (autograft) is standard treatment for patients diagnosed with multiple myeloma and in certain patients with lymphoma. Mobilization failure limits the number of patients who can proceed to autograft. The minimum generally recommended cell dose for a single autograft procedure is 2 310 6 cluster differentiation (CD)341 cells/kg recipient body weight, 1 although the optimal number may be >5 310 6 CD341 cells/kg. 2 Most initial mobilization protocols use either granulocyte-colony stimulating factor (G-CSF) alone or G-CSF in combination with chemotherapy. However, up to 30% of patients fail to mobilize the minimum CD341 cell dose with standard mobilization schedules incorporating G-CSF 6 chemotherapy. 3, 4 Failure rates for second mobilization attempts using G-CSF or G-CSF plus chemotherapy schedules are over 70%. 3 Plerixafor (Mobozil, AMD3100) is a CXC chemokine receptor (CXCR4) chemokine receptor antagonist that blocks the interaction between the CXCR4 receptor expressed on CD341 cells and stromal cell-derived factor 1a, which is expressed on stromal cells. This results in mobilization of stem cells into the peripheral blood. 5 In Europe, plerixafor is indicated in combination with G-CSF to enhance mobilization of hematopoietic stem cells to the peripheral blood for collection in patients with lymphoma or multiple myeloma whose cells mobilize poorly. 6 It should be noted that unlike the US licence, plerixafor's European licence includes use in Hodgkin lymphoma as well as non-Hodgkin lymphoma (NHL). Three main strategies have been used when incorporating plerixafor in PBSC mobilization strategies, and there has been no general consensus on nomenclature for these 3 strategies; however, the preferred terms used in our consensus statement are given in bold below, with definitions.
Plerixafor may be used after a prior failed mobilization as part of a second or subsequent mobilization procedure ("delayed re-mobilization").
Plerixafor may be introduced in the course of a mobilization episode in order to improve the harvest results when a standard mobilization procedure is predicted to fail ("pre-emptive use"; synonyms include "rescue" or "just-in-time" use). 7, 8 Pre-emptive use of plerixafor may be incorporated either into mobilization regimens using G-CSF alone, or into regimens combining chemotherapy with G-CSF.
Finally, "Up-front" (ie planned first-line) use of plerixafor has also been investigated, although it is unlikely to be the most cost-effective approach for the majority of patients.
In 2012 we formed a Plerixafor Usage Working Party Group with representative clinicians from UK and Irish sites. Although plerixafor is widely used, particularly in the management of patients in whom mobilization had previously failed, published guidance on its use in autologous stem cell mobilization is limited. This article aims to review the existing literature on the use of plerixafor in delayed re-mobilization following previous mobilization failure, existing literature on its use in a pre-emptive setting, plus audit data from the working group members to produce a consensus statement. This consensus statement identifies those patients who may benefit from the use of plerixafor in mobilization and the specific criteria for its use are determined. An attempt has been made to develop a protocol that is sufficiently detailed to be of genuine usefulness to end-users in a real-world setting, but that is not overly proscriptive and still allows scope for individual centers to tailor it to local practice. through a literature search of relevant medical databases such as PubMed.
The consensus statement was developed by a joint working party, which held 3 meetings during 2012 and 2013. This consensus statement is based on a review of published evidence, expert opinion and audit data on usage of plerixafor from the group members. Where differences in protocols and practice were identified from review of the group members' experience, the group was asked to agree on an appropriate consensus position.
Two single-center clinical audits are published herein for the first time. First, a comparative audit of cryopreservation volume carried out at University College Hospital, London to determine the impact of prior mobilizing chemotherapy, and of plerixafor, on total nucleated cell (TNC) count in the PBSC product (and hence on cryopreservation volume) is summarized in Table 1 . Second, an audit carried out in Glasgow of CD341 cell doses obtained when day-of-collection pre-apheresis peripheral CD341 count was <20 ml 21 is summarized in Table 2 . For both audits, patients and methods are detailed in the legend to the relevant table.
| F I ND IN GS

| Initial plerixafor safety and efficacy studies in autologous PBSC mobilization
The initial pivotal phase III studies assessing plerixafor as an autologous PBSC mobilizing agent were performed in patients with NHL 9 and myeloma 10 who were eligible for Abbreviation: G-CSF, granulocyte colony stimulating factor; PBSC, peripheral blood stem cell; WBC, white blood cell. Note: Summary of experience from University College London stem cell laboratory, previously unpublished, and published here for the first time by permission (M. W.). 499 consecutive autologous collection procedures on adult patients with lymphoma or myeloma were audited, along with a comparator group of 408 allogeneic collections performed with G-CSF only during the same temporal period. The use of prior mobilizing chemotherapy substantially reduces the WCC at apheresis and consequently the TNC in the PBSC product compared with G-CSF-only mobilization, but the addition of plerixafor has little or no independent impact. The higher TNC observed when PBSC collection is performed without mobilizing chemotherapy (irrespective of the use of plerixafor) will impact on cryopreservation volume, as it is standard practice to dilute PBSC products to reduce TNC concentration below a pre-determined limit before freezing, so as to reduce nutritional stress on the cells. /kg in the NHL study and 6 310 6 /kg in the myeloma study) with plerixafor plus G-CSF than with placebo plus G-CSF (59% vs. 20% in the NHL study and 71.6% vs. 34.4% in the myeloma study; P < .001). The NHL study also addressed engraftment following autologous PBSC transplant, which was comparable in the 2 groups.
Useful clinical data on the efficacy of plerixafor plus G-CSF as "delayed re-mobilization" for patients who had failed prior conventional autologous PBSC collection approaches was obtained from Genzyme's Compassionate Use Programs (CUPs) in the USA 11 and subsequently in Europe. 12 Plerixafor was made available free of charge by Genzyme for remobilization of patients with myeloma or lymphoma requiring autologous PBSC transplant and who had previously failed to achieve a minimum transplantable CD341 dose (generally 2 310 6 /kg) following conventional mobilization. CUP patients usually received plerixafor following 4 days of G-CSF 10 mg/kg/day, and following a previous failed PBSC mobilization attempt (ie this was "delayed re-mobilization"). G-CSF plus plerixafor could be continued daily for up to 7 days with apheresis after each dose of plerixafor, although in practice very few patients received more than 3 aphereses. Of 115 patients who participated in the CUP in the USA, 11 76 achieved a CD341 dose of 2 310 6 /kg (60.3% of patients with NHL, 71.4% with myeloma and 76.5% with Hodgkin lymphoma). The majority of patients had satisfactory engraftment, with median 11 days to neutrophil engraftment and 18 days to platelet engraftment. Similar results were described in a subsequent series of 56 consecutive patients from the European CUP in Spain and the UK, 12 with achievement of a CD341 dose of 2 3 10 6 /kg by 42 patients (75%) receiving G-CSF plus plerixafor. All of the 35 patients (63%) who had been transplanted at the time of publication had engrafted satisfactorily. Despite some concerns that the definitions used in the CUP protocol may have underestimated the success rate for plerixafor (because patients who achieved a transplantable PBSC dose by pooling PBSC collected with plerixafor with PBSC from previous mobilization episodes were counted as "mobilization failures" rather than "successes"), both of these initial publications suggest a considerably higher re-mobilization success rate for "delayed re-mobilization" with plerixafor plus G-CSF than had previously been described following /kg being achieved in 6 of the 7 patients. A multi-center series from Italy, Austria and the UK 14 subsequently described preemptive use of plerixafor in 13 patients with lymphoma or myeloma who were failing chemomobilization. All 13 patients mobilized a minimum transplant dose of >2 3 10 6 / kg CD341 cells in 1-3 aphereses, with no drug-related serious adverse events. At the time of publication, engraftment had been satisfactory for the 5 patients for whom data were available. Plerixafor was introduced if peripheral CD341 count was below a pre-determined threshold following mobilizing chemotherapy. At least 3 similar series have been published subsequently from other European centers (reviewed in Jantunen & Lemoli 15 ). In the USA, a prospective, multicenter, open-label, sequential phase II study has been published assessing the use of plerixafor along with chemomobilization, although this was not strictly speaking on a pre-emptive basis. 16 Patients received mobilizing chemotherapy, and apheresis was initiated when the peripheral CD341 count exceeded 20 ml
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. Daily plerixafor was initiated after the first apheresis. A total of 40 patients received plerixafor; in general it was well tolerated with the only serious adverse events reported being unlikely to be associated with plerixafor use. There was a significant increase (mean 2.06-fold) in the PBSC product between apheresis day 1 (pre-plerixafor) and day 2 (post-plerixafor).
Plerixafor may also be introduced pre-emptively in the course of a G-CSF-based PBSC mobilization episode without combined chemotherapy. 17, 18 Although this strategy can be highly cost-effective, 18 the use of plerixafor along with G-CSF and without prior mobilizing chemotherapy can lead to problems with excessive cryopreservation volumes compared with PBSC collected after chemotherapy-based mobilization. This is a consequence of PBSC collection without prior mobilizing chemotherapy, rather than a direct effect of Plerixafor, as demonstrated by previously unpublished clinical audit data from University College London presented in Table 1 . Note that "cryopreservation volume" should not be confused with the initial PBSC product volume as it comes off the cell separator machine. Larger cryopreservation volumes most commonly occur due to dilution of high-count products prior to cryopreservation to achieve a TNC concentration below a pre-defined limit, so as to reduce nutritional stress on the cells during storage, cryopreservation and/or thawing. 19 
| UK experience to date with rescue plerixafor
The West of Scotland experience with rescue plerixafor was described initially in a European Society for Blood and Marrow Transplantation (EBMT) 2011 abstract 20 and in a ). Pre-emptive plerixafor was prescribed during 47 of a total of 286 mobilization episodes (16%), with mean usage of 1.58 doses per patient. For patients requiring plerixafor, the success rate at achieving a transplantable CD341 dose (>2.5 3 10 6 /kg CD341 cells/kg under local policy) at first plerixafor use was 91% (39 of 43 patients). Overall mobilization success rate at first mobilization attempt was 98.6% (39 of 43 receiving plerixafor plus all 239 patients not requiring plerixafor). The introduction of plerixafor was estimated to have reduced a historical failed PBSC mobilization rate of 15% to 20%, to <2%. Further details are given in Table 3 .
Data were also presented at EBMT 2011 on clinical experience with rescue plerixafor following chemomobilization at Nottingham University Hospitals. 23 Plerixafor was used pre-emptively to rescue failing chemomobilization for eligible myeloma patients undergoing PBSC mobilization with cyclophosphamide (3 g/m 2 ) and G-CSF (5 lg/kg). Plerixafor was introduced on day 13 if peripheral CD341 count was <10 ml 21 . In total 12 of 46 patients required preemptive plerixafor, of whom 8 collected >2 3 10 6 /kg CD341 cells and proceeded to autologous PBSC transplant following high-dose melphalan (200 mg/m 2 ), with normal engraftment. Six patients required 1 dose and 6 patients required 2 doses of plerixafor. This strategy was therefore effective in reducing PBSC mobilization failure from 26% to <5%. Further details are given in Table 3 .
In both these audits, the estimated incremental drug cost per patient was <£2000 (approximately equivalent to 2300 Euros or $2400 USD at the time of writing) to make rescue plerixafor universally available for patients failing chemomobilization, assuming a cost per plerixafor 24 mg vial in the UK of approximately £5000. In the Nottingham audit, 23 plerixafor was required by 12 of 46 patients with a mean of 1.5 vials per patient, giving an incremental drug cost of (£5000 31.5 3 12/46 5) £1956 (2252 Euros or $2378 USD) per myeloma patient in the autologous transplant program as a whole. In the Glasgow audit, 21 plerixafor was required by 16% of patients with a mean of 1.58 vials per patient, giving an incremental drug cost of £1264 (1456 Euros or $1536 USD) per patient in the autologous transplant program as a whole, as discussed in the abstract text. These figures are obviously based on the UK cost per vial for plerixafor but are unlikely to differ greatly in other countries. Neither of these audits collected data on cryopreservation or storage costs. However, the data presented in Table 1 suggest that plerixafor itself does not impact on cryopreservation volumes, and is likely to be cost-neutral in terms of PBSC cryopreservation and storage.
| Optimization of apheresis protocols after plerixafor
It is generally accepted that a peripheral CD341 count of 20 ml 21 predicts a high likelihood of achieving a transplantable cell dose, 24 but most UK centers will now initiate apheresis for patients mobilizing more poorly once peripheral CD341 counts are 10 ml 21 following either chemomobilization or G-CSF-only mobilization. 25 Apheresis
should not however be attempted if the peripheral CD341 count is <5 ml
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. 26 Although some centers still use Sysmex "progenitor cell" count or total and/or differential WBC count as triggers for initiation of apheresis rather than flow cytometric peripheral CD341 count, the use of peripheral CD341 count has been shown to give better outcomes. 27 An audit in Glasgow (prior to plerixafor availability) of all PBSC collection procedures carried out with peripheral CD341 counts <20 ml /kg (see Table 2 for details). Given that day 1 apheresis yield <1 3 10 6 /kg has been suggested to be predictive of failed overall mobilization, 28, 29 these data suggest that most patients with peripheral CD341 count >15 ml 21 on first apheresis day will achieve a transplantable cell dose, while patients with peripheral CD341 counts of 10-15 ml 21 are at risk of mobilization failure. For this reason, 15 ml 21 appears a more rational trigger for pre-emptive plerixafor use than 10 ml
. The threshold of 15 ml 21 is also the level at which preemptive plerixafor becomes cost-effective in an algorithmbased US study which incorporates economic modeling, and in a second large single-center retrospective cohort study from a different US center (both discussed in more detail below 17, 18 ). Most cell separators will default to process 2 blood volumes in a standard hematopoietic progenitor cells apheresis collection. However, large-volume leukapheresis (ie processing of 3 blood volumes or more) has been shown to increase
CD341 cell collection 30 and should be considered in patients undergoing autologous HPC-A collection with peripheral CD341 count below 20 ml 21 at the time of apheresis. 31 This also applies to patients who have received plerixafor. Approximate prediction of CD341 cell dose is possible at the start of a PBSC collection procedure using benchmark collection efficiency for the cell separator being used, recipient weight, peripheral CD341 count and the volume of blood to be processed, and this can be extremely useful in gauging the optimal blood volume to process during each procedure. 32 
| Previous published algorithms for pre-emptive plerixafor use during failing PBSC mobilization
Several previous algorithms have been published for the preemptive use of plerixafor during failing PBSC mobilization, either during "steady-state" (G-CSF-only) mobilization or during chemomobilization. 18, 24, 29, [33] [34] [35] However, in brief, we consider that our suggested algorithm discussed below has the following advantages over almost all previously published algorithms: (a) it is applicable to any mobilization protocol, including many different chemomobilization approaches as well as "steady-state" mobilization; (b) it suggests a pre-apheresis peripheral CD341 threshold of 15 ml as the usual trigger for plerixafor usage, rather than the thresholds of either 10 or 20 ml 21 used in other algorithms, and UK experience (as summarized in Tables 2 and 3 ) suggests that 15 ml 21 is the optimal threshold; and (3) it is simple. With the partial exception of a single-center algorithm from Atlanta, Georgia which shares several features of our recommended algorithm, 17 none of the previously published algorithms combine these 3 advantages. Costa et al. 18 have developed and validated an algorithm that includes costeffectiveness calculations, resulting in a "sliding scale" of peripheral CD341 count threshold for plerixafor usage depending on target CD341 cell dose. The suggested peripheral CD341 threshold if collecting for a single transplant with target CD341 dose of 2.5 to 3 3 10 6 /kg corresponds closely with our suggested 15 ml 21 threshold (see Costa et al. 18 , fig. 3 ). However, the algorithm suggested is based on mobilization with G-CSF alone and therefore not applicable to chemomobilization. Cheng et al. 33 and Farina et al. 34 advocate a trigger peripheral CD341 count for plerixafor usage of 10 ml 21 which we believe to be too low for reasons discussed earlier. Milone et al. 29 recommend a trigger peripheral CD341 count of 20 ml 21 which we believe may be too high; in addition, like Farina et al. 34 , the algorithm used is applicable only to one or 2 specific chemomobilization protocols. Sorasio et al. 35 suggest a rather complex algorithm which requires peripheral CD341 count to be performed following chemomobilization at a timepoint when the patient's total white cell count (WCC) is still only 1 3 10 9 /l; this is unlikely to be optimally cost-effective and is not standard UK practice, given that most patients achieve peak peripheral CD341 counts after chemomobilization only once total WCC has regenerated to normal levels. The EBMT consensus statement 24 makes recommendations that are not inconsistent with what we have suggested below. However, due to the requirements for this consensus article to conform to widely differing practice in different countries, the recommendations remain rather loose, stating for instance that for a pre-apheresis CD341 count of 10-20 ml
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, there should be "a dynamic approach based on the patient's disease characteristics and treatment history". 24 There is also no discussion of the appropriate timepoint (in terms either of total WCC or of days post-chemotherapy) for plerixafor decision-making following chemomobilization. Finally, a retrospective cohort study from Atlanta, Georgia 17 evaluated mobilization outcomes in 2 cohorts of patients before and after the 2008 US regulatory approval of plerixafor, and found that a peripheral CD341 cell count <15 ml 21 and total WCC of >10 3 10 9 /l following at least 5 days of G-CSF predicted mobilization failure with 91% specificity and 78% positive predictive value, and these parameters were therefore recommended as a "trigger" for pre-emptive plerixafor usage. In reality, a large proportion of the patients in this series had received chemomobilization, and hence the recommended algorithm was to give plerixafor either if peripheral CD341 count was <15 ml 21 after 5 days of G-CSF if used alone (which would virtually always result in total WCC > 10 3 10 9 /l), or if peripheral CD341 was <15 ml 21 on the first day of total WCC recovery to >10 3 10 9 /l following chemomobilization. This is similar to our own recommendations, except that we recommend a plerixafor "decision point" based on peripheral CD341 count < 15 ml 21 either after 4 days (rather than 5 days) of G-CSF if used without mobilizing chemotherapy, or at the time of WCC recovery to >4 3 10 9 /l (rather than 10 3 10 9 /l) following chemomobilization. Despite the somewhat earlier "decision points" in our own protocol, it has not resulted in over-usage of plerixafor in clinical practice (see Table 2 ).
| Published experience in off-label plerixafor use
Plerixafor is currently licensed in Europe for mobilization of autologous PBSC for transplantation from adult patients with lymphoma or myeloma failing to achieve a transplantable PBSC dose by conventional means. 6 However, there have been several publications discussing off-label use in conditions other than lymphoma or myeloma.
Autologous PBSC transplant is now widely used in the treatment of childhood cancers, including solid tumors as well as lymphomas. Autologous PBSC mobilization in children can often be challenging due to the intensity of chemoradiotherapy regimes received earlier in the course of treatment, and due to increasing use of sequential high-dose therapy that requires higher PBSC doses. Although plerixafor remains unlicensed in children, results have been published in abstract form from a series of 40 children from 19 centers worldwide who had PBSC mobilized with plerixafor off-licence, mostly on the US or European CUPs. 36 A transplantable CD341 dose of >2 3 10 6 /kg was achieved in 70% of mobilization episodes incorporating plerixafor. A total of 16 potential plerixafor toxicities were reported, but all were graded mild or moderate; the most common were injection site reactions and gastrointestinal toxicity. Although this remains the largest single case series to date, there are also large published single-center series with similar findings in terms of safety and efficacy, notably a series of 33 children mobilized with G-CSF plus plerixafor in Moscow that also included evidence of satisfactory engraftment following subsequent autologous PBSC transplant. 37 Experience with 33 patients, predominantly adults, from the European plerixafor CUP who had non-hematological malignancies has also been published. 38 Some 85% (n 5 28) mobilized successfully following plerixafor, with a median CD341 cell dose of 5 3 10 6 /kg. Neutrophil and platelet engraftment were satisfactory for the 19 patients who had been transplanted at the time of publication.
In patients with autoimmune disease, autologous hematopoietic stem cells may be derived from peripheral blood or bone marrow, but PBSCs are easier to harvest and tend to engraft better. 39 Although there is little published evidence to support the use of plerixafor in autoimmune disease, it may be a reasonable option (in combination with G-CSF) in patients with poor mobilization after a prior attempt with cyclophosphamide priming. 39 Plerixafor therefore may offer an effective remobilization strategy when used off-label for patients with diagnoses other than lymphoma or myeloma who are candidates for autologous PBSC transplant but have failed conventional mobilization approaches. However, longer-term safety of plerixafor has not yet been demonstrated in these patient groups, and there are potential concerns regarding the possibility of tumor cell mobilization, which might in theory increase relapse rates due to re-infusion of malignant cells with the PBSC product. This is a particular concern in acute promyelocytic and other leukemias, since plerixafor has been shown to mobilize leukemic stem cells in animal studies. 40 Off-label use of plerixafor should therefore be subject to careful case-by-case risk assessment, with the patient's full informed consent.
| D IS C US S I ON
| Recommendations for plerixafor in the UK for patients with lymphoma or myeloma who mobilize PBSC poorly by conventional means
There is now considerable published evidence to support the use of plerixafor for patients with lymphoma or myeloma who mobilize PBSC poorly by conventional means. Plerixafor already has approval from the Scottish Medicines Consortium for use within NHS Scotland, 22 and more recently has also been approved by NHS England's Clinical Commissioning Group. 7 The question is therefore not one of whether plerixafor should be used, but of how it should be used, and in what circumstances. The main points on which guidance may be useful are:
Delayed re-mobilization with G-CSF plus plerixafor, versus pre-emptive use in the course of a failing mobilization episode.
"Trigger" peripheral CD341 count at which pre-emptive plerixafor may be indicated after mobilization with 4 days of G-CSF 10 mg/kg/day without mobilizing chemotherapy.
"Trigger" peripheral CD341 count and total WBC count at which pre-emptive plerixafor may be indicated after chemomobilization.
Whether there should be a minimum peripheral CD341 count below which pre-emptive plerixafor is not appropriate.
Whether there is any role for up-front (ie first-line) use of plerixafor in patients who are predicted poor mobilizers based on factors such as extensive prior chemotherapy and/ or radiotherapy.
When to stop if plerixafor has not resulted in successful PBSC mobilization.
As discussed, there is substantial published evidence suggesting that both "delayed re-mobilization" with plerixafor plus G-CSF and pre-emptive plerixafor use are safe and effective approaches. To date, no direct comparative studies between these 2 approaches have been published. However, the single-center experiences from 2 large UK transplant centers discussed earlier 21, 23 suggest that a pre-emptive approach is no less effective than delayed re-mobilization in terms of the proportion of patients who achieve a transplantable CD341 dose after plerixafor, and also suggest that plerixafor usage is unlikely to be significantly higher if a preemptive approach is used in preference to "delayed remobilization". In particular, the Glasgow experience has shown that using peripheral CD341 count < 15 ml 21 on the first day of
total WCC recovery to 4 3 10 9 /l following chemomobilization (or peripheral CD341 count <15 ml 21 after 4 days of G-CSF if used without prior chemo) as a routine trigger for plerixafor use is an effective strategy that has proven applicable to a wide variety of chemomobilization protocols, and that does not lead to excessive plerixafor usage. This same algorithm has subsequently been used with similarly good outcomes at other UK centers (Consensus Group members, personal communications). We note the recommendation in the American Society for Blood and Marrow Transplantation (ASBMT) guidelines 8 that "each center should develop and implement its own algorithms for applying various mobilization strategies". Nevertheless, UK experience has been that CD341 cell mobilization generally does coincide with hematopoietic recovery following chemomobilization, and that our recommended strategy based on peripheral CD341 cell count at the time of total WCC recovery following the post-chemotherapy nadir, rather than on a set number of days post-chemotherapy, is clinically effective and costeffective in practice. Chemomobilization is more widely used in the UK than in the USA, and apheresis centers are likely to be referred patients for autologous PBSC collection using a wider range of chemomobilization protocols, making it more challenging for individual centers to develop local regime-specific protocols. Our experience has confirmed that the timings of hematopoietic recovery and peak peripheral blood CD341 count both vary depending on the myelotoxicity of the mobilizing chemotherapy regime used, with both being later for more myelotoxic regimes. We recognize that if using our recommendations, apheresis centers will need to know for scheduling purposes approximately when to expect hematopoietic recovery following particular chemomobilization regimes, since it is wasteful and inconvenient to the patient for them to be seen for peripheral CD341 count either too early or too late after chemotherapy. We therefore include in our Recommendations a table based on historical audit at several large UK centers Table 4 , giving expected timing of hematopoietic recovery (ie first day of total WCC 4 3 10 9 /l) following a variety of widely used chemomobilization regimes, along with some recommendations for chemotherapy and apheresis scheduling.
Pre-emptive plerixafor use has obvious advantages in terms of avoiding delay of the patient's transplant pending a second mobilization attempt 4 or more weeks later. It is . Although recognizing that any peripheral CD341 count threshold for plerixafor use must inevitably be somewhat arbitrary, <15 ml 21 is backed up by historical UK data (Table 2 ) and has proven to be both clinically effective and cost-effective in UK practice (Glasgow data, Table 3 ). It has been suggested that a day 1 apheresis yield of <1 3 10 6 /kg CD341 cells, 29, 30 of <1. 3 3 10 6 /kg CD341 cells 42 or of less than half the target total CD341 cell dose 43 is predictive of failure to achieve a transplantable CD341 dose, and should therefore additionally be used as a trigger for pre-emptive plerixafor. We recommend that pre-emptive plerixafor use is reasonable if day 1 apheresis yield is <1 3 10 6 /kg. A more controversial question is whether there is a minimum peripheral CD341 count threshold below which preemptive plerixafor use should not be attempted, because it is unlikely to be effective. There is limited published evidence on which to base an opinion. In an Italian prospective survey of 215 patients with myeloma or lymphoma who received plerixafor, 41 the drug was found to be most clinically effective if given when peripheral CD341 count was 4 ml
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; however, some of the patients in this series who received plerixafor when peripheral CD341 count was < 4 ml 21 still achieved successful PBSC collection. Conversely, in a case series from Poland and Croatia, pre-emptive plerixafor was found to be equally effective for patients with a peripheral CD341 count <3 ml 21 as for patients with higher CD341 count levels. 44 Similar results were seen in a large series from Barcelona, where plerixafor was still effective in rescue of G-CSF-only mobilization where day 4 peripheral CD341 count was <3.5 ml
. 45 In the 2 UK audits summarized in Table 3 , all of the 5 patients who failed to mobilize despite pre-emptive plerixafor had peripheral CD341 counts <5 ml 21 at the time of pre-emptive plerixafor use, indicating a higher risk of plerixafor failure in these patients. Nevertheless, a significant proportion of patients with peripheral CD341 counts <5 ml 21 did achieve a transplantable cell dose following pre-emptive plerixafor in both audits. Although more information is still required on the effectiveness of plerixafor in this setting, we cautiously recommend that pre-emptive plerixafor should still be attempted in such circumstances.
Plerixafor is an expensive drug, and clinicians have a duty not to use it in situations where it is unlikely to be effective. Both common-sense and our own clinical experience would suggest that if the patient's peripheral CD341 count has not risen to >10 ml 21 after an initial dose of plerixafor, then further plerixafor use in the current mobilization episode is unlikely to be appropriate. However, the UK experience to date has confirmed previous published data 46 suggesting that plerixafor is frequently capable of inducing successful PBSC mobilization in the course of a second separate mobilization episode, even when it has failed or only been partially successful in the course of an initial mobilization episode. We therefore recommend that if plerixafor has not resulted in successful PBSC collection during the patient's initial mobilization episode, then a second mobilization attempt (either chemomobilization or G-CSF alone) incorporating plerixafor is appropriate. There is ongoing debate on whether there is any role for up-front (ie first-line) use of plerixafor in patients who are predicted poor mobilizers based on factors such as extensive prior chemotherapy and/or radiotherapy. Some groups, such as the Italian Gruppo Italiano Trapianto di Midollo Osseo (GITMO) group, have sought to identify predicted poor mobilizers using factors such as extensive prior chemotherapy and/or radiotherapy, age 65 years, refractory disease, low baseline platelet count (ie before starting the mobilization regime) and/or extensive bone marrow involvement, 47 and have cautiously suggested that plerixafor could be considered up-front in such patients. Our own view is that this is unlikely to be either the most cost-effective or the most clinically effective approach. Due to the relatively weak correlation between these various pre-collection risk factors and the actual PBSC cell dose achieved, a substantial proportion of patients who would be predicted to mobilize PBSC poorly based on risk factors such as those identified by the GITMO group actually achieve successful PBSC collection without the use of plerixafor. Conversely, a substantial proportion of poor mobilizers would not have been identified as being at risk based on these known pre-collection risk factors. We suggest that even for patients predicted to be at risk of poor mobilization due to pre-collection risk factors such as those mentioned, an approach of pre-emptive plerixafor use based on peripheral CD341 counts in the course of a mobilization episode is therefore more clinically effective, and significantly more cost-effective, than the alternative approach of using plerixafor up-front for patients predicted to be poor mobilizers. It is noted that the ASBMT guidelines 8 suggest that up-front plerixafor may be appropriate 'if the goal is the highest possible CD341 cell collection yield, if real-time CD341 cell counts are not available, or if fewer apheresis days is the top priority': while broadly endorsing this advice, we also note that all 3 of these scenarios are uncommon in UK practice. Up-front plerixafor is not currently re-imbursed on a routine basis by UK National Health Service commissioning groups, and requires prior authorization by Individual Patient Treatment Request.
| Potential limitations
We recognize that our consensus statement does have potential limitations. We have cited data from 2 UK single-center studies that have so far only been published in abstract form (Table 3) , as well as data from 2 previously unpublished single-center audits (Tables 1 and 2 ). The aim here was to include relevant data based on real-world UK practice; however, we recognize that the inclusion of non-peer-reviewed abstract data may weaken the strength of some of our recommendations. Similarly, the advice on apheresis timings given in Table 4 has not as yet been independently validated by a non-UK center. Nevertheless, we believe that our suggested algorithm for plerixafor use is both detailed and flexible, and that it may therefore be of relevance to apheresis practitioners both within and outside the UK.
| R ECOM M ENDA TI ONS
| General principles
1. Plerixafor is indicated for patients with lymphoma or myeloma who mobilize PBSC poorly by conventional means, either as delayed re-mobilization along with G-CSF for patients who have failed to achieve a transplantable PBSC dose after a prior PBSC mobilization episode, or pre-emptively in the course of a failing mobilization episode (grade 1B recommendation). and/or transplant slots, and also in terms of avoiding the negative quality-of-life impact of failed PBSC mobilization, and is therefore cautiously recommended as the best approach to plerixafor use in most circumstances (grade 2C recommendation).
| Pre
3. Pre-emptive use may be triggered by a peripheral CD341 count <15 ml 21 at the time of WBC recovery to normal levels following chemomobilization, by a peripheral CD341 count <15-20 ml 21 after 4 days of G-CSF if being used without prior mobilizing chemotherapy, or by a first day's apheresis yield of <1 310 6 CD341 cells/kg (grade 1C recommendation). Our suggested decisionmaking algorithm is summarized in Figure 1 .
4. Although patients with peripheral CD341 counts below 5 ml 21 do appear to be at higher risk of mobilization failure despite pre-emptive plerixafor, there is no absolute minimum peripheral CD341 count threshold below which preemptive plerixafor may not be used (grade 2C recommendation).
| Up-front use of plerixafor
5. As noted in the ASBMT guidelines, 8 up-front (planned first-line) use of plerixafor may be appropriate for patients who require an unusually high CD341 cell dose (most often to support 2 or more cycles of high-dose chemotherapy), or in situations where a day-of-apheresis peripheral CD341 count is not available. These situations are however rare in UK practice, and up-front use of plerixafor is therefore not appropriate for the majority of patients (grade 1C recommendation).
5.4 | When to stop when plerixafor has not resulted in successful PBSC collection 6 . If the patient's peripheral CD341 count has not risen to >10 ml 21 after an initial dose of plerixafor, then further plerixafor use in the current mobilization episode is unlikely to be appropriate (grade 2C recommendation).
7. If plerixafor has not resulted in successful PBSC collection during the patient's initial mobilization episode, then a second mobilization attempt (either chemomobilization or G-CSF alone) incorporating plerixafor is appropriate (grade 1C recommendation).
8. It is rarely appropriate for a single patient to receive more than 3 doses of plerixafor, and almost never appropriate for a single patient to receive more than 4 doses of plerixafor, in order to obtain PBSC to support a single high-dose procedure (grade 2C recommendation).
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